TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22409388
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal system (BTDS) 20 μg/h
Study: 18605968
Drug: Tight control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight control of hypertension (mean dose of methyldopa 1267±406 mg)
Study: 1486160
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg flumazenil
Study: 21933335
Drug: Biopsy recommended
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsy recommended due to elevated PSA level (≥ 3 ng/mL)
Study: 20535457
Drug: AZD0837 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0837 450 mg extended‐release formulation once daily for 8 days
Study: 20535457
Drug: Cimetidine co-administered
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine co-administered on Days 6‐8 during both treatment periods
Study: 17650832
Drug: High-dose inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inhaled beclomethasone (1,500 microg/d)
Study: 16271314
Drug: bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion XL 150-300 mg
Study: 26654280
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg)
Study: 22787176
Drug: Intensive multifactorial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multifactorial treatment
Study: 23822603
Drug: PROLASTIN (alpha1-proteinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROLASTIN (alpha1-proteinase inhibitor (human), intravenous)
Study: 15221407
Drug: Topical heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical heat treatment
Study: 15221407
Drug: Static stretching
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static stretching treatment
Study: 15221407
Drug: Heat plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat plus static stretching treatment
Study: 8432269
Drug: Atracurium 0.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.23 mg kg‐1
Study: 27537264
Drug: Ranibizumab plus
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab plus intravitreal dexamethasone implant (IVC)
Study: 27537264
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (IVM and IVC)
Study: 18475166
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no add-on medication)
Study: 16609067
Drug: R-CHOP therapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP therapy (n = 113)
Study: 16609067
Drug: CHOP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP therapy (n = 85)
Study: 16609067
Drug: R-CHOP and
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP and CHOP therapy
Study: 8641505
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH‐a) treatment
Study: 8641510
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of GnRH‐a treatment
Study: 8641510
Drug: GnRH‐a treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a treatment
Study: 26746121
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg buspirone
Study: 24007934
Drug: Carbohydrate-rich fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich fluid (Preop(®), 50 kcal/100 ml)
Study: 22089860
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment with BCAA
Study: 22089860
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment with ACE-I
Study: 14745283
Drug: rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and clarithromycin 250 mg b.d. (RLC-1 group)
Study: 14745283
Drug: rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and clarithromycin 500 mg b.d. (RLC-2 group)
Study: 11534303
Drug: 20 IU
Normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU syntocinon in 20 ml 0.9% NaCl saline intraumbilically (group 1)
Study: 11534303
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.9% NaCl saline (group 2)
Study: 2725884
Drug: CY 208-243
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CY 208-243 (5 to 40 mg)
Study: 4595485
Drug: Fenfluramine (80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (80-120 mg daily)
Study: 16672046
Drug: Dipyridamole-atropine (Dipatro:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole-atropine (Dipatro: 0.84 mg/kg over 10 min i.v. dipyridamole with addition of up to 1 mg of atropine)
Study: 15911161
Drug: Rectal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal placebo (RP)
Study: 15911161
Drug: Rectal lidocaine
Normalized name: LIDOCAINE 50 mg in 1 g TOPICAL CREAM [Walgreens Anorectal Lidocaine Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal lidocaine (RL)
Study: 12150499
Drug: 10-100 mg
Normalized name: carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-100 mg sildenafil
Study: 10458714
Drug: abciximab (12-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (12-hour administration)
Study: 10458714
Drug: abciximab (24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (24-hour administration)
Study: 7789047
Drug: Nebulized inhaled
Normalized name: Hydra-Neb Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized inhaled morphine 25 mg
Study: 26115618
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum adiponectin (mean 14.3 ± 6.6 μg/ml)
Study: 26115618
Drug: Baseline urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline urine adiponectin:creatinine (Uadp/cr) (mean 126.8 ± 178.9 μg/ml)
Study: 23639045
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg lenalidomide
Study: 18022084
Drug: Assist device
Normalized name: inhaler, assist devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assist device therapy
Study: 11561270
Drug: Intrathecal mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal mixture containing bupivacaine 0.125% and sufentanil 0.75 microg/mL with epinephrine 1.25 microg/mL
Study: 11561270
Drug: Intrathecal mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal mixture containing bupivacaine 0.125% and sufentanil 0.75 microg/mL without epinephrine
Study: 25609219
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose)
Study: 25609219
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with dronedarone (moderate CYP3A4 inhibitor)
Study: 9088816
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg, twice, at 12 h intervals (25 patients)
Study: 22650127
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment group (cotton sheet moxibustion combined with plum-blossom-needle tapping therapy)
Study: 22650127
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group (Acyclovir ointment, Valaciclovir Hydrochloride tablets, Vitamin B1)
Study: 18363746
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E 15% and 10% ointment
Study: 18363746
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E 10% ointment
Study: 18363746
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E ointments
Study: 11677109
Drug: Gemcitabine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine at 1000 mg/m2 days 1 and 8 with carboplatin AUC 4.5
Study: 11677109
Drug: Gemcitabine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine at 1000 mg/m2 days 1 and 8 with carboplatin AUC 5
Study: 29603851
Drug: 0.75 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/d of atrasentan
Study: 29603851
Drug: 1.25 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/d of atrasentan
Study: 23329850
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated tetravalent dengue vaccine (LATV)
Study: 17186795
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate spray 0.05%
Study: 29098908
Drug: Vehicle spray
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle spray
Study: 12962529
Drug: Galantamine 24
Normalized name: galantamine 24 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 24 mg/day for 12 months (6 months double-blind and 6 months open-label)
Study: 10831024
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium (target serum concentration of 75 microg/mL for 2 weeks)
Study: 29257943
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine 1.8 mL as a buccal injection and 0.2 mL as a palatal injection
Study: 29257943
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine 1.8 mL plus normal saline 0.2 mL as a palatal injection
Study: 29257943
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine 3.6 mL plus normal saline 0.2 mL as a palatal injection
Study: 22026393
Drug: Statins (including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (including atorvastatin, pravastatin, rosuvastatin, simvastatin)
Study: 17520105
Drug: Atorvastatin (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10-40 mg/day)
Study: 18303246
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration within 3 hours from stroke onset
Study: 17154093
Drug: External irradiation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External irradiation (as monotherapy)
Study: 17154093
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (orbital radiation with high-dose intravenous steroid pulse treatment)
Study: 10753020
Drug: Oral food
Normalized name: Nutritional Supplement Oral Food, Solid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral food challenges with placebo
Study: 1558898
Drug: Fenfluramine hydrochloride
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine hydrochloride (60 mg/os)
Study: 26525553
Drug: BG cream
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG cream with 2-week follow-up (BG1)
Study: 26525553
Drug: BG cream
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG cream with 8-week follow-up (BG2)
Study: 24332263
Drug: RW-SAIL (standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: RW-SAIL (standardized glycerinated short ragweed sublingual allergen immunotherapy liquid)
Study: 11422545
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy without cognitive counter conditioning
Study: 29226626
Drug: GSK2982772 (0.1-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 (0.1-120 mg single ascending doses)
Study: 29226626
Drug: GSK2982772 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 (20 mg tablets vs capsules)
Study: 18952910
Drug: 135 mg
Normalized name: cocaine 135 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg ABT‐335 alone
Study: 18952910
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 40 mg rosuvastatin and 135 mg ABT‐335
Study: 12414411
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% applied four times daily for 3 days before surgery
Study: 31791688
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel 80 mg/m2 and carboplatin AUC5 or AUC6 every 3 weeks (Group 2)
Study: 21880911
Drug: CRF(1) antagonist
Normalized name: CRF
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRF(1) antagonist GW876008
Study: 15615349
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of drugs with complementary mechanisms
Study: 11977649
Drug: Pre-operative intra-arterial
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative intra-arterial infusion chemotherapy (mitomycin 10 mg, 5-FU 1,000 mg, epirubicin 60 mg)
Study: 2576397
Drug: CV 205‐502
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV 205‐502 (0.05 mg daily)
Study: 2576397
Drug: CV 205‐502
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV 205‐502 (mean 0.09 mg a day)
Study: 795022
Drug: 0.50 g
Normalized name: SALICYLIC ACID 0.50 g in 100 g TOPICAL SOAP [ORIPAN GOLD 100g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 g a day of penicillamine
Study: 795022
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg a day of zinc metal supplement with 0.50 g a day of penicillamine
Study: 795022
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg a day of zinc metal supplement with 1 g a day of penicillamine
Study: 795022
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 0.50 g a day of penicillamine
Study: 795022
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 1 g a day of penicillamine
Study: 795022
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with zinc supplement
Study: 27592680
Drug: Immunoglobulin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin (200 mg)
Study: 27592680
Drug: Combination lactoferrin/immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination lactoferrin/immunoglobulin (200 mg/800 mg)
Study: 25760977
Drug: Intermittent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent docetaxel chemotherapy (DOC 70 mg/m² every 3 weeks for eight cycles with a fixed 3-month interval after the first four courses)
Study: 25760977
Drug: Continuous docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous docetaxel chemotherapy (DOC 70 mg/m² every 3 weeks for eight cycles)
Study: 22268979
Drug: Mindfulness-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based treatment (MBT, n = 12)
Study: 22268979
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment (CBT, n = 8)
Study: 18779611
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m(2))
Study: 8942008
Drug: D'Allergen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: D'Allergen treatment
Study: 6125483
Drug: Tofizopam (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofizopam (100 mg)
Study: 6125483
Drug: Tofizopam (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofizopam (100 mg, three times)
Study: 25715664
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose X-ray examination (0.365 mSv)
Study: 8781825
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg t.i.d.) as adjuvant therapy to standard therapy
Study: 8781825
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (thrombolysis, beta-blockers, and nitrates)
Study: 1464341
Drug: Captopril (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (both doses)
Study: 6099135
Drug: Alpha 2-adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha 2-adrenoceptor agonist alpha-methylnoradrenaline (MNA)
Study: 19665770
Drug: Milk oral
Normalized name: lytes/dextros/mvn/AA/ging/milk ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk oral immunotherapy (MOIT)
Study: 25362822
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of omega-3
Study: 25362822
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of omega-3
Study: 24023786
Drug: simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 40 mg
Study: 2894081
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of flurbiprofen and terfenadine
Study: 31866308
Drug: Caffeine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (150 mg 3 x daily for 10 days)
Study: 31866308
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 x daily for 10 days)
Study: 31866308
Drug: Withdrawal (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal (150 mg caffeine 3 x daily for eight days, followed by placebo for two days)
Study: 23772581
Drug: Medical and
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical and rehabilitation treatment (Group 1)
Study: 23772581
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (Group 2)
Study: 15525889
Drug: Percutaneous Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous Ethanol Injection (PEI)
Study: 6255535
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg daily)
Study: 3664330
Drug: Nystatin (500,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin (500,000 units four times daily)
Study: 22149546
Drug: hsCRP in
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsCRP in subjects with NAFLD (4.2±1.2 mg/L)
Study: 7576895
Drug: Selenium supplemented
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplemented formula (17 micrograms Se/L)
Study: 7576895
Drug: Unsupplemented formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupplemented formula (4.6 micrograms Se/L)
Study: 2156764
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon cream (IFN) - 9 x 10(6) IU applied deep into the vagina every night for 2-week courses 1 week apart, for a total treatment period of 12 months.
Study: 21562449
Drug: Tacrolimus (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (mean level 7.2 ± 2.54 ng/mL)
Study: 21562449
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) (mean dose 1.5 ± 0.61 g/day)
Study: 16490760
Drug: Magnesium gluconate
Normalized name: Magnesium Gluconate
DrugBank: Magnesium gluconate (DB13749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium gluconate (i.v. bolus of 0.21 mmol kg(‐1) followed by a continuous infusion of 0.03 mmol(‐1) kg(‐1) h(‐1))
Study: 7839784
Drug: 2 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg.kg‐1 of racemic ketamine
Study: 7839784
Drug: 1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg.kg‐1 of S‐(+) ketamine
Study: 7839784
Drug: 0.1 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg.kg‐1 of midazolam (prior administration)
Study: 3277779
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg boluses every 6 hours
Study: 3277779
Drug: Ranitidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine infusion (125 micrograms/kg.h)
Study: 14633757
Drug: i.v. midazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. midazolam sedation (titrated at 0.5 mg x min(‐1), maximum 5 mg)
Study: 12207629
Drug: Metered Dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler (MDI)
Study: 6378239
Drug: Cold-adapted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted recombinant virus vaccine (A/Washington/80, H3N2)
Study: 19254354
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Acotiamide
Study: 19254354
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Acotiamide
Study: 16896273
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg and Atorvastatin 10 mg
Study: 9310278
Drug: Mustard oil
Normalized name: mustard oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mustard oil (alpha-linolenic acid, 2.9 g/day)